NewsRx

Search our medical news database

HIV Gene Therapy

New Wave Protease Inhibitor Would Avoid Resistance

Published in AIDS Weekly, December 4th, 1995

A gene-therapy approach might overcome a major obstacle to the new class of drugs targeting HIV protease: the rapid appearance of drug-resistant viral mutants.

Researchers Lilia M. Babe et al. of the University of California, San Francisco, report the development of dominant negative HIV genes that express inactive forms of the HIV protease gene, thereby disrupting viral replication ("Trans-Dominant Inhibitory Human Immunodeficiency Virus Type 1 Protease Monomers Prevent Protease Activation and Virion Maturation," Proceedings of the National Academy of Sciences, October 24, 1995;92(22):10069-73).

Dominant negative mutants have been developed for...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook